An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.
2023-01-19
عنوان الدراسة
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.
داعم الدراسة
Novartis
دواء الدراسة
ABL001 (Asciminib), Imatinib, Nilotinib, Bosutinib
رقم بروتوكول الدراسة
CABL001A2001B
حالة الدراسة
Ongoing
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。